仇萌教授在Adv. Funct. Mater.期刊上发表题为“Nanopoxia: Targeting Cancer Hypoxia by Antimonene-Based Nanoplatform for Precision 

Cancer Therapy”(https://onlinelibrary.wiley.com/doi/10.1002/adfm.202104607)的文章，文章摘要如下：

Abstract：

Most anticancer drugs with broad toxicities are systematically administrated to cancer patients and their distribution in tumors is  

extremely low owing to hypoxia, which compromises the therapeutic efficacies of these cancer drugs. Consequently, a preponderant 

proportion of cancer drugs is distributed in off-target-healthy tissues, which often causes severe adverse effects. Precision cancer therapy 

without overdosing patients with drugs remains one of the most challenging issues in cancer therapy. Here, a novel concept of nanopoxia 

is presented, which is a tumor-hypoxia-based photodynamic nanoplatform for the release of therapeutic agents to achieve precision 

cancer therapy. Under tumor hypoxia, exposure of tumors to laser irradiation induces the fracture of polymer outer shell and produces 

anticancer reactive oxygen species, and switches 2D antimonene (Sb) nanomaterials to cytotoxic trivalent antimony to synergistically kill 

tumors. In preclinical cancer models, delivery of Sb nanomaterials to mice virtually ablates tumor growth without producing any 

detectable adverse effects. Mechanistically, the tumor hypoxia-triggered generation of trivalent antimony displays direct damaging 

effects on cancer cells and suppression of tumor angiogenesis. Together, the study provides a proof-of-concept of hypoxia-based 

precision cancer therapy by developing a novel nanoplatform that offers multifarious mechanisms of cancer eradication.